As we come across any information on Clinical Trials, we will post them here. We also encourage you to share any information with us by posting on our Forum by clicking here or sending us a message via our Contact Us page. Please Share!
11/20/2019
Click here for PDF of current trials updated November 20, 2019
- Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary
Study Number: NCT03206177
Learn More - Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib
Study Number: NCT03651206
Learn More - Trial on Trabectedin In The Treatment of Advanced Uterine And Ovarian Carcinosarcoma (CS) MITO 26
Study Number: NCT02993705
Learn More - Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma
Study Number: NCT00687687
Learn More - Cabozantinib Plus Nivolumab and Ipilimumab Women With Recurrent Gynecologic Carcinosarcoma
Study Number: NCT04149275
Learn More - Pazopanib vs. Pazopanib Plus Gemcitabine (PazoDoble)
Study Number: NCT02203760
Learn More - Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy (PRECISE)
Study Number: NCT03933761
Learn More - Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment
Study Number: NCT04106414
Learn More - Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus
Study Number: NCT00025506
Learn More - Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the Uterus
Study Number: NCT00502203
Learn More
6-25-2018
Below is a list of Clinical Trials found on clinicaltrials.gov that accept patients with carcinosarcoma and are currently recruiting.
Please visit a study’s website for more information about inclusion and exclusion criteria.
To find detailed information on a study, please go to web address for each trial. If the link does not work, go to https://www.clinicaltrials.gov/ and enter the NCT number (study number).
- A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Relapsed/ Refractory Endometrioid Endometrial or Endometrioid Ovarian Cancer (P204) (P204)
- Study Number: NCT03395080
- https://clinicaltrials.gov/ct2/show/study/NCT03395080
- Locations: AL, FL, MA, MS, TN
- Principal Investigator: Rebecca Arend, MD, University of Alabama at Birmingham
- Paclitaxel (Taxol) –antimicrotubule agent
- DKN-01–an inhibitor of DKK1, which modulates both the canonical and noncanonical Wnt signaling pathway
- Please note that the description of this study on the clinicaltrials.gov website does not include carcinosarcoma; however, the study is accepting patients with carcinosarcoma. It has also recently been expanded to include patients with epithileal ovarian cancer and carcinosarcoma.
2. A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies.
- Study Number: NCT03241173
- https://clinicaltrials.gov/ct2/show/NCT03241173
- Locations: At UAB and 34 other sites (US, Spain, Switzerland and UK)
- Study Director: John E. Janik, MD, Incyte Corporation
- INCAGN01949 – an anti-OX40 agonist antibody
- Combination therapy with Nivolumab (Opdivo), a programmed death receptor-1 (PD-1) blocking antibody
- Combination therapy with Ipilimumab (Yervoy), blocks the CTLA-4 protein so that the T-cells stay switched on and active to attack cancer cells. CTLs are cytotoxic T lymphocytes.
3. A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949in Subjects With Advanced or Metastatic Solid Tumors
- Study number: NCT02923349
- https://clinicaltrials.gov/ct2/show/NCT02923349
- Locations: 8 sites (US – NJ, NY, TN, TX), Spain, Switzerland and UK
- INCAGN01949 – an anti-OX40 agonist antibody
- Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)_MITO 26 (MITO 26)
- Not yet recruiting, but study started in 2018
- Study Number: NCT02993705
- https://clinicaltrials.gov/ct2/show/NCT02993705
- Location: Milan
- Contact: Domenica Lorusso, MD, +390223903697
- Trabectedin – an alkylating agent
- Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary
- Study Number: NCT03206177
- https://clinicaltrials.gov/ct2/show/NCT03206177
- Location: Oklahoma
- Study Chair: Kathleen Moore, MDF, University of Oklahoma
- Galunsertib – a TGFβ inhibitor
- A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer
- Study Number: NCT03015129
- https://clinicaltrials.gov/ct2/show/NCT03015129
- Locations: Memorial Sloan Kettering in NY and NJ
- Principal Investigator: Vicky Makker, MD, Memorial Sloan Kettering Cancer Center
- Durvalumab – an anti-PD-L1 (programmed death ligand 1)
- Tremelimumab – an immune checkpoint blocker (against CTLA-4)
- Vorinostat (SAHA) in Uterine Sarcoma
- Study Number: NCT03509207
- https://clinicaltrials.gov/ct2/show/NCT03509207
- Location: Graz, Austria
- Principal Investigator: Edgar Petru, Department of OB/GYN of the Medical University of Graz, Austria
- Vorinostat (Zolinza) – an HDAC-inhibitor. The study is for patients whose tumor shows a high expression of HDAC.
- A study of Nivolumab in Selected Uterine Cancer Patients
- Study Number: NCT03241745
- https://clinicaltrials.gov/ct2/show/NCT03241745
- Locations: Memorial Sloan Kettering in NY and NJ
- Principal Investigator: Clair Freidman, MD, Memorial Sloan Kettering Cancer Center
- Nivolumab (Opdivo) – a programmed death receptor-1 (PD-1) blocking antibody
- Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Recruiting
- Study Number: NCT03552471
- https://clinicaltrials.gov/ct2/show/NCT03552471
- Location: Ohio State University Comprehensive Cancer Center
- Principal Investigator: Floor Backes, MD, Ohio State University Comprehensive Cancer Center
- Mirvetuximab Soravtansine – Antibody Drug Conjugate for patients with folate receptor alpha (FRα)-positive (targets folate receptor-α)
- Rucaparib Camsylate (Rubraca), a PARP inhibitor
- Patients must have confirmation of folate receptor-a (FR-alpha) positivity by immunohistochemistry (IHC)
- Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endomentrial Cancer (SAVE)
- Study Number: NCT03422198
- https://clinicaltrials.gov/ct2/show/NCT03422198
- Location: Huntsman Cancer Institute/University of Utah
- Principal Investigator: David Gaffney, Huntsman Cancer Institute/University of Utah
- For patients post hysterectomy and free from residual disease
- Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
- Study Number: NCT02834013
- https://clinicaltrials.gov/ct2/show/NCT02834013?term=NCT02834013&rank=1
- Locations: 831 study locations in the US
- Principal Investigator: Sandip Patel, Southwest Oncology Group
- Nivolumab (Opdivo) – a programmed death receptor-1 (PD-1) blocking antibody
- Ipilimumab (Yervoy) – blocks the CTLA-4 protein so that the T-cells stay